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Tanshinone I (T1) and tanshinone II (T2) are themajor diterpenes isolated fromDanshen (SalviamiltiorrhizaBunge).Three human
lung adenocarcinoma cell lines, A549, CL1-0, and CL1-5, were treated with T1 and T2 for the in vitro antitumor test. Results showed
that T1 was more effective than T2 in inhibiting the growth of lung cancer cells via suppressing the expression of VEGF, Cyclin A,
and Cyclin B proteins in a dose-dependent manner. Moreover, a transgenic mice model of the human vascular endothelial growth
factor-A
165
(ℎ𝑉𝐸𝐺𝐹-𝐴
165
) gene-induced pulmonary tumor was further treated with T1 for the in vivo lung cancer therapy test. T1
significantly attenuated hVEGF-A
165
overexpression to normal levels of the transgenic mice (Tg) that were pretreated with human
monocytic leukemia THP-1 cell-derived conditioned medium (CM). It also suppressed the formation of lung adenocarcinoma
tumors (16.7%) compared with two placebo groups (50% for Tg/Placebo and 83.3% for Tg/CM/Placebo; 𝑃 < 0.01). This antitumor
effect is likely to slow the progression of cells through the S and G2/M phases of the cell cycle. Blocking of the tumor-activated
cell cycle pathway may be a critical mechanism for the observed antitumorigenic effects of T1 treatment on vasculogenesis and
angiogenesis.
1. Introduction
According to statistics supplied by the TaiwaneseDepartment
of Health, pulmonary cancer is the most common invasive
malignancy and the leading cause of cancer deaths in Taiwan
[1]. Pulmonary cancer, according to the biocharacteristics
and the clinical manifestation, can be divided into two gross
types including small cell lung cancer and nonsmall cell
lung cancer. According to the statistics of epidemiology in
Taiwanese district, among patients with lung cancers, the
ratio of patients of small cell lung cancer is only 12%–15%
and the ratio of patients of nonsmall cell lung cancer is
about 85%–88%. The nonsmall cell lung cancer primarily
includes pulmonary squamous cell carcinoma, pulmonary
large cell lung carcinoma, and pulmonary adenocarcinoma
[2]. Pulmonary adenocarcinoma induces a tumor resulted
from cells classified as secretory cells including Clara cell,
type II alveolar cells, and mucin producing cells. Pulmonary
adenocarcinoma commonly occurs in the peripheral of lung
(about 2/3) and the other 1/3 of it starts proliferation from
the center of lung [3]. Upon forming a tumor by pulmonary
adenocarcinoma in a patient, it will cause distal metastasis to
other organs including brain, kidney, liver, and bone in 80%of
patients.Therefore, many researchers have searched for more
effective treatments to cure pulmonary adenocarcinoma
[4].
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In the early stages of cancer, the out-of-control prolifer-
ation of cancer cells leads to a deficiency of both nutrients
and oxygen that causes a large degree of cell death.Therefore,
an inflammation response occurs, and hypoxia-inducible
factor-1𝛼 (HIF-1𝛼) is activated.TheHIF-1𝛼 activation induces
secretion of a large quantity of vascular endothelial growth
factor-A
165
(VEGF-A
165
). The secreted VEGF-A
165
binds to
VEGFR2 receptor and activates a downstream signal that
induces vasculogenesis [5, 6]. When cancer cells secrete a
large amount of VEGF-A
165
, vasculogenesis is induced so
as to provide sufficient nutrition and oxygen to the tumor,
thus increasing tumor growth rate. It is well known that
the expression level of VEGF-A
165
is positively related to
the growth and spread of cancer cells [7]. Therefore, the
development ofmedicines that target VEGF-A
165
is a popular
topic of study.
Traditional medicine usually contains various bioactive
phytochemicals with the chemoprevention and therapy of
cancer [8]. Danshen (Salvia miltiorrhiza Bunge) is a tra-
ditional medicine that has been used in China for over a
thousand years to treat various diseases, including coronary
artery disease, cerebrovascular disease, heart disease, hep-
atitis, and cancer [9–11]. Over 40 tanshinone compounds
have been isolated and identified from Danshen. Of these,
tanshinone I (T1), tanshinone II (T2), and cryptotanshinone
(CTS) are the three major diterpene compounds [11, 12],
which possess anticancer properties [8]. Furthermore, T1
reduced the growth of leukemia [13–16], lung cancer [17], and
breast cancer [18] in in vitro cell cultures via induction of
apoptosis.
In this study, an expression vector carrying a mouse
Clara cell secretory protein (mCCSP) gene promoter and the
human V𝑒𝑔𝑓-𝐴
165
gene cDNA sequence was constructed.
Then, the expression vector was introduced into the embryos
of FVB mice by a microinjection process and the embryos
were transplanted into the fallopian tubes of femalemice.The
embryos are allowed to develop into the newborn mice and
the hVEGF-A
165
is capable of expressing in the lung bronchus
epidermal cells of the transgenic mice. The transgenic mouse
carrying ℎV𝑒𝑔𝑓-𝐴
165
gene, which induces pulmonary tumor,
was used as an in vivo lung cancer therapy model.
T1 had antitumorigenic and antimetastatic effects in
CL1-5-bearing SCID mice when coinjected with condition
medium (CM) which is a serum-free medium with 24 h
incubation with phorbol myristate acetate-treated human
monocytic leukemia THP-1 cells [17]. Previous studies
showed that the CM contains proinflammatory cytokines
such as TNF-𝛼, IL-1, IL-8, and IL-12; anti-inflammatory
cytokines such as TGF-𝛽, IL-4, IL-10, and IL-13; and IL-6
with both proinflammatory and anti-inflammatory proper-
ties [19–23]. Previous reports have shown that the imbalance
between proinflammatory and anti-inflammatory cytokines
can influence neoplastic outcome [19]. Lee et al. [17] showed
that the CM treatment alone would invoke inflammation and
neovascularization and promote tumor growth due to the
abundant proinflammatory cytokines. Thus, in this study a
strain of human ℎV𝑒𝑔𝑓-𝐴
165
-induced lung tumorigenic trans-
genic mice was used to research the regulatory mechanism of
T1 coinjected with CM against pulmonary adenocarcinoma.
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Figure 1: Active components of tanshinone I (T1) and tanshinone
II (T2) extracted from a Chinese traditional medicine, Danshen
(Salvia miltiorrhiza Bunge), and the cell viability of human lung
cancer cell lines after T1 and T2 treatments. (a) Chemical structure
of T1. (b) Chemical structure of T2. (c) Effects of T1 and T2 over a
range of concentrations (1, 5, 10, 25, and 50𝜇M) on the cell viability
of A549, CL1-0, and CL1-5 cells after 24 h incubation.
2. Methods
2.1. Chemicals. Tanshinone I (1,6-dimethyl-phenanthro
[1,2-b]furan-10,11-dione) (purity 99%) and tanshinone II
(1,6,6-trimethyl-6,7,8,9-tetrahydrophenanthro [1,2-b]furan-
10,11-dione) (purity 99%) were obtained from Formosa
Kingstone Bioproducts International (Taipei, Taiwan)
(Figure 1). Tanshinones were isolated from the root of S.
miltiorrhiza Bunge.
2.2. Cell Line. Thehumanmonocytic leukemia cell line THP-
1 (ATCC TIB 202; American Type Culture Collection) was
grown in RPMI 1640 (Invitrogen Corp., Carlsbad, CA, USA)
supplemented with 1.5 g/L Na
2
HCO
3
, 4.5 g/L glucose, and
10% fetal bovine serum (FBS). The cell line was incubated
at 37∘C in 5% CO
2
. Before the experiments, THP-1 cells
were pretreated with 3.2 × 107mole/L phorbol myristate
acetate (Sigma-Aldrich Corp., St. Louis, MO, USA) for 24 h.
The preparation of conditioned medium (CM) derived from
phorbol myristate acetate-pretreated THP-1 cells has been
described previously [24]. Human lung adenocarcinoma
cell lines, A549, CL1-0, and CL1-5 cells, were cultured in
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Dulbecco’smodified Eagle’s medium (DMEM) supplemented
with 10% FBS. Cells were incubated at 37∘C in 5% CO
2
.
2.3. Cell Viability on Tumor Cells by MTT Assay. To measure
the cytotoxicity of tanshinone I and tanshinone II on cell
proliferation, A549, CL1-0, and CL1-5 cells (2 × 105 cells/well)
were seeded into a 96-well plate in triplicate and preincubated
for 3 h to allow cell adherence. First, 200 𝜇L of fresh medium
containing various concentrations (1, 5, 10, 25, and 50𝜇M)
of tanshinone I and tanshinone II was added into the
cultures and incubated at 37∘C for 24, 48, and 72 h under
humidified air containing 5% CO
2
. Following the removal
of the medium from the wells, 100𝜇L of tetrazolium salt
solutions (1mL MTT in 10mL DMEM) was added. After
4 h of incubation at 37∘C, the medium was removed and
100 𝜇L of DMSOwas added to dissolve the formazan crystals.
Absorbance was measured in an enzyme-linked immunosor-
bent assay (ELISA) reader at 570 nm. The cell viability ratio
(%) was calculated from the following equation: % viability =
(absorbance of test sample/absorbance of control) × 100.
2.4. Transgenic Mouse Production and Validation. The
mccsp-hVEGF-A
165
-sv40 transgenic mice were generated by
pronuclear microinjection. A 1975-bp transgene fragment,
consisting of mCCSP promoter, ℎ𝑉𝐸𝐺𝐹-𝐴
165
cDNA, and
SV40 poly(A) signal sequence, was obtained from the
plasmid with NruI-SapI double-digestion. The purified
transgene was microinjected into the male pronuclei
of fertilized eggs from superovulated female mice and
transferred to recipient pseudopregnant females [22].
To detect the hVEGF-A
165
transgene in transgenic mice
with a homozygous (hVEGF-A
165
+/+) or heterozygous
(hVEGF-A
165
+/−) genotype, the mice were rapidly screened
for the foreign gene by PCR analysis [25]. The exogenic
human VEGF-A
165
protein expression levels in homozygous
(hVEGF-A
165
+/+) or heterozygous (hVEGF-A
165
+/−)
transgenic mice were also detected by western blot [25].
In this study, we used the homozygous (hVEGF-A
165
+/+)
genotype to evaluate the anticancer effects of T1.
2.5. Animals. The transgenic mice and wild-type FVB strain
mice were sustained on a standard laboratory diet and
distilled water ad libitum and kept on a 12-hour light/dark
cycle at 22 ± 2∘C. This study was conducted according to
institutional guidelines and approved by the Institutional
Animal Care and Utilization Committee of National Chung
Hsing University, Taiwan (IACUC No. 96-83). For the exam-
ination of both VEGF expression and pulmonary function,
the transgenicmice with the homozygous genotype (hVEGF-
A
165
+/+) were normally distributed to three groups (𝑛 = 6)
and treated as follows: (1) PBS alone (Tg/Placebo group),
(2) CM alone (Tg/CM/Placebo group), and (3) T1 (1mg/kg
body weight) suspended in CM (Tg/CM/T1 group). Three
groups were injected intraperitoneally (i.p.) three times a
week. In addition, wild-type FVB strain mice (𝑛 = 6) were
used as a normal control group. Experimental mice were
sacrificed at the age of 10 months old after stimulation by CM
duringmonths 2–4 and 6–10 and then receiving T1 or placebo
administration at months 6–10. Pulmonary tissues were
collected for pathological histology, immunohistochemical
(IHC) staining [26, 27], and RNA [28] and protein extraction.
2.6. Measurement of Airway Hyperresponsiveness (AHR).
To evaluate AHR in the Tg/Placebo, Tg/CM/Placebo, and
Tg/CM/T1 groups, bronchial provocation tests were per-
formed using methacholine. First, the basal pulmonary
function was measured; then, saline and methacholine
(12.5mg/mL) were converted to aerosols using a nebulizer;
finally, the mice inhaled the aerosolized compounds five
times through a Rosenthal-French dosimeter. Three minutes
later, a pulmonary function test was performed. The pul-
monary function at each step was measured 30 times with
a portable microspirometer, and the enhanced pause (penh)
values were selected as the pulmonary function value [25].
2.7. Pathological Histology. Lung tissue was fixed in 10%
buffered formaldehyde (pH7.0), embeddedwith paraffin, sec-
tioned into 3 𝜇m sections, and examined using hematoxylin
and eosin (H&E) staining as described previously [29, 30].
2.8. Immunohistochemistry (IHC) Staining. Formaldehyde-
fixed and paraffin-embedded sections were cut to a thickness
of 5 𝜇m, deparaffinized and rehydrated in a gradient of
alcoholic solutions, and then treated with boiling water for
15 minutes. The sections were incubated in 3% hydrogen
peroxide for 10min to block endogenous peroxidase activity
and then incubated overnight at 4∘C with primary rabbit
monoclonal antibody against hVEGF-Ausing a 1 : 40working
dilution. For antigen retrieval, the sections were immunos-
tained with the VECTASTAIN ABC kit (Universal, Vector
Lab., Burlingame, CA, USA) in accordance with the manu-
facturer’s specifications. Diaminobenzidine (DAB) was used
for stain development, and the sections were counterstained
with hematoxylin [31]. The negative control consisted of
substituting normal serum for primary antibody.
2.9. Real-Time RT-PCR. Total RNA was extracted from lung
tissue using Trizol reagent (Invitrogen, Carlsbad, CA, USA),
as specified by the manufacturer. The total RNA (2𝜇g) was
then resuspended in 9𝜇L of diethylpyrocarbonate-(DEPC-)
treated water, and the first strand of cDNA was synthesized
with random primers using ImProm-II reverse transcriptase
(Promega, USA) in a total volume of 20𝜇L. The reaction was
carried out at 42∘C for 1 h. For further PCR amplification, an
aliquot (1 : 10) of theRTproductwas adjusted to contain 0.1𝜇g
of each primer, and additional buffer was added to a total
volume of 20 𝜇L. RT-PCRwas performed in aThermal Cycler
2720. Real-time RT-PCR was performed using SYBR Green
in a Rotor-Gene 6000 [26]. To evaluate gene expression, real-
time RT-PCR was performed on 6 genes (nrp-1, kdr, mmp2,
egfr, erk2, and survivin) using cDNA from pulmonary tissue.
The cDNA of 𝛽-actin was used as an internal control.
2.10. Western Blotting. CL1-0 cells were seeded on a 10 cm
dish for 2 h; afterward, the cells were pretreated with T1
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Figure 2: Expressions of VEGF, Cyclin A, and Cyclin B protein in
CL1-0 cells treated with T1 after 24 h incubation. (a) Western blot
analysis of VEGF, Cyclin A, and Cyclin B protein expressions in
CL1-0 cells after being treated with different concentrations of T1 (0,
1, 5, 10, and 25𝜇M) for 24 h. (b) The quantification data of protein
expression levels under different concentrations of T1 treatment.
(1, 5, 10, and 25 𝜇M) for 24 h. The expressions of VEGF,
Cyclin A, and Cyclin B proteins were measured by western
blotting. Pulmonary tissues were homogenized in 500𝜇L of
RIPA buffer (5mM Tris-HCl pH 7.4, 0.15M NaCl, 1% NP40,
0.25% sodium deoxycholate, 5mM EDTA, and 1mM ethy-
lene glycol-bis (2-aminoethyl-ether)-N, N, N, N-tetraacetic
acid). The homogenates were centrifuged at 12,000 g for
30 minutes at 4∘C. Protein (40 𝜇g) was then separated by
SDS-PAGE in 10% polyacrylamide and electrotransferred
to polyvinylidene difluoride membranes. The membranes
were incubated in blocking solution (5% BSA) at room
temperature for 2 h. The membranes were then incubated
with primary antibody (VEGF-A, ERK2, Cyclin A, Cyclin
B, and GAPDH) overnight at 4∘C. After washing, the mem-
braneswere incubatedwith a goat anti-rabbit IgGperoxidase-
conjugated secondary antibody directed against the pri-
mary antibody. The membranes were developed using an
enhanced chemiluminescence western blot detection system
as described previously [32].
2.11. Statistical Analysis. Experimental values are expressed
as the mean ± standard error (SE). All data were analyzed
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Figure 3: The schedule of animal trials and the effect of tanshinone
I on airway hyperresponsiveness (AHR) parameters of pulmonary
function. (a) The experimental designation for evidence-based
lung tumorigenesis attenuation in animal trial. T1 was injected
intraperitoneally (i.p.) at 1mg/kg b.w. three times a week. Mice
were sacrificed at 10 months of age after T1 administration for 4
months. (b) The Penh (enhanced pause) is a dimensionless value
that represents a function of the proportion of maximal expiratory
to maximal inspiratory box pressure signals and of the timing
of expiration. Data were presented as mean ± SEM (𝑛 = 6).
The AHR was measured at 6, 7, and 8 months. WT: wild-type
FVB mice; Tg/Placebo: hVEGF-A
165
+/+ transgenic mice without T1
supplement; Tg/CM/Placebo: conditionmedium-treated transgenic
mice without T1 supplement; Tg/CM/T1: condition medium treated
transgenic mice with T1 supplement; NS: normal saline; MCh:
methacholine.
using t-tests. Statistical significances are presented as 𝑃 <
0.05 (∗) or 𝑃 < 0.01 (∗∗).
3. Results
3.1. Effects of T1 and T2 on Cancer Cell Viability. A549, CL1-0,
and CL1-5 cells, which are human lung adenocarcinoma cell
lines, were treated with the major active components isolated
fromDanshen, tanshinone I (T1; Figure 1(a)) and tanshinone
II (T2; Figure 1(b)) at concentrations of 1, 5, 10, 25, and 50 𝜇M
for 24, 48, and 72 h.This treatment decreased the cell viability
in a concentration-dependent manner when compared with
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Figure 4: Photographs of whole lungs (a) and stained histopathologic slides of lung tissues (b) from wild-type-FVB mice, hVEGF-A
165
+/+
transgenic mice (Tg/Placebo), condition medium-treated transgenic mice (Tg/CM/Placebo), and condition medium treated transgenic mice
with T1 supplement (Tg/CM/T1) groups. Tissues from the Tg/CM/T1 group were taken from 10-month-old hVEGF-A
165
overexpressing
transgenic mice after T1 administration for 4 months. The tissue sections were stained with H&E and photographed at 200x magnifications.
Scale bar = 5mm.
Table 1: Lung tumorigenesis frequency of wild type, Tg/Placebo, Tg/CM/Placebo, and Tg/CM/T1 groups in the mouse lung tissues (n = 6)
using histopathological image analysis.
Variable Wild type Tg/Placebo Tg/CM/Placebo Tg/CM/T1
Normal 100 (100%) 0 (0%) 0 (0%) 2 (33.3%)
Cyst 0 (0%) 2 (33.3%) 0 (0%) 3 (50%)
Damaged alveoli 0 (0%) 3 (50%) 4 (66.7%) 3 (50%)
Mild emphysematous change 0 (0%) 2 (33.3%) 0 (0%) 3 (50%)
Prominent emphysematous change 0 (0%) 3 (50%) 3 (50%) 1 (16.7%)
Hemosiderin-laden macrophages in alveoli 0 (0%) 3 (50%) 5 (83.3%) 1 (16.7%)
Old hemorrhage 0 (0%) 1 (16.7%) 2 (33.3%) 1 (16.7%)
Moderate lymphocytic infiltration 0 (0%) 2 (33.3%) 4 (66.7%) 1 (16.7%)
Marked chronic lymphoid infiltration 0 (0%) 2 (33.3%) 4 (66.7%) 1 (16.7%)
Neoplasm 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%)
Lymphoma 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%)
Adenocarcinoma 0 (0%) 3 (50%) 5 (83.3%) 1 (16.7%)
controls (Figure 1(c)). In MTT assay, T1 was more effective
than T2, and the IC
50
values of T1 were 8.9, 1.8, and 2.0 𝜇M
for A549, CL1-0, and CL1-5 cells at 24 h, respectively. Of these
cancer cells, T1 was able to successfully inhibit the growth of
CL1-0 cells.
3.2. T1 Suppressed VEGF, Cyclin A, and Cyclin B Pro-
tein Expressions in CL1-0 Lung Cancer Cells. As shown in
Figure 2(a), T1 inhibited the expressions of VEGF, Cyclin A,
and Cyclin B protein in a dose-dependent manner. Approxi-
mately 77%, 60%, and 25% reductions of VEGF, CyclinA, and
Cyclin B protein were observed at 10 𝜇M, as determined with
densitometry analysis (Figure 2(b)). At concentrations of up
to 10 𝜇M, T1 could almost completely inhibit the expression
of Cyclin A, and Cyclin B proteins in CL1-0 cells. Thus, T1
warrants further development as a cancer-prevention agent.
3.3. Effect of T1 on AHR Parameters of Pulmonary Func-
tion. A strain of transgenic mice carrying ℎV𝑒𝑔𝑓-𝐴
165
gene,
which induces pulmonary tumor, was used as an in vivo
lung cancer model for test of T1 therapeutic effects. The
animal trials timeline was shown in Figure 3(a). It is well
known that AHR is an important measure of pulmonary
function, and hyperresponsiveness to methacholine (MCh)
is an indicator of lung function. In this study, the AHR
was measured at 6, 7, and 8 months. At 6 months, penh
values for the wild type, Tg/Placebo, Tg/CM/Placebo and
Tg/CM/T1 groups treated with methacholine were 0.84, 1.50,
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Figure 5: Immunohistochemical (IHC) staining of VEGF expression in lung tissues of the wild-type FVB mice, hVEGF-A
165
+/+ transgenic
mice (Tg/Placebo), Tg/CM/Placebo, and Tg/CM/T1 groups. Tissues were taken from 10-month-old experimental mice after T1 or PBS
administration for 4 months. Sections were stained with primary rabbit monoclonal antibody against human VEGF-A using a 1 : 40 working
dilution. Upper panels were observed under 100x magnifications, and lower panels were observed under 200x magnifications.
2.46, and 1.80, respectively; at 7 months, they were 0.82,
2.24, 3.70, and 2.07, respectively; and at 8 months, they were
1.03, 4.17, 4.87, and 2.01, respectively (Figure 3(b)). Thus, the
Tg/CM/T1 experimental group treated with 1mg/kg b.w. of
T1 showed significantly lower penh values when compared to
Tg/CM/Placebo group (𝑃 < 0.01).
3.4. Effect of T1 on Pathological Histology. Figure 4 and
Table 1 showed that various degrees of progressing pul-
monary tumors were formed in the transgenic mice and
primarily consisted of neoplasms growing on the periphery
of the pulmonary alveolus and adenomas growing adjacent
to the lung bronchus. In the pulmonary alveolus of the
lung bronchus of transgenic mice, some large-grained pink
cells were clearly visible. These pink cells were identified
as macrophages, which are indicative of an inflammation
response (Figure 4). These results show that hVEGF-A
165
is
capable of promoting vascular permeability and an inflam-
mation response. Furthermore, CM treatment alone invoked
inflammation and neovascularization as well as promoted
lung adenocarcinoma growth (83.3%; 5/6) compared with Tg
alone (50%; 3/6), which may be due to various proinflam-
matory cytokines. Treatment with T1 might have an effect
on the balance of proinflammatory and anti-inflammatory
cytokines by eliminating the proinflammatory cytokines and
then significantly reduced lung tumor growth (16.7%; 1/6) as
shown in Table 1.
Angiogenesis is an important factor in the formation of
tumors as well as in tumor growth, invasion, and metastasis.
VEGF promotes the initial formation of new blood vessels
(vasculogenesis) and plays a vital role in the growth and
expansion of these new blood vessels (angiogenesis). Using
IHC staining, we found that hVEGF was overexpressed
in Clara cells of lung tissue from the Tg/Placebo group
(Figure 5). Clearly, Tg/CM/Placebo group significantly ele-
vated VEGF overexpression in Clara cells compared with
the Tg/Placebo group. Interestingly, the treatment with T1
(1mg/kg b.w.) significantly blocked VEGF overexpression in
Clara cells when compared to the Tg/CM/Placebo group.
These results indicate that T1 can reduce hVEGF overexpres-
sion, which could in turn eliminate the formation and growth
of new blood vessels.This is a possible explanation for howT1
can effectively block tumor growth, invasion, andmetastases.
3.5. T1 Causes Suppression of Tumor-Formation Signal Genes.
The mRNA expression patterns of nrp-1, kdr, mmp2, egfr,
erk2, and survivin in the Tg/Placebo, Tg/CM/Placebo, and
Tg/CM/T1 groups were assessed using real-time RT-PCR
(Figure 6). T1 did not regulate mCCSP promoter in our
internal test (see Figure S1 in Supplementary Material avail-
able online at http://dx.doi.org/10.1155/2013/319247); thus T1
directly effected VEGF expression. Furthermore, when com-
pared to Tg/Placebo group, CM treatment alone increased
the expression of mmp2 (𝑃 < 0.05), which is believed
to be involved in tumor angiogenesis due to its matrix-
degrading capacity. However, in this study, treatment with
T1 normalized the expression of mmp2. In addition, CM
treatment alone markedly increased the mRNA levels of erk2
(𝑃 < 0.05), which is involved in the regulation of different
cellular processes, from apoptosis to cell proliferation and dif-
ferentiation. We observed a statistically significant decrease
in the levels of activated erk2 in the Tg/CM/T1 group in
comparison with Tg/CM/Placebo group.
3.6. T1 Causes Suppression of Cell Cycle Progression Signaling
Pathways. Western blotting showed that VEGF, Cyclin A,
and Cyclin B were downregulated in the Tg/CM/T1 group
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Figure 6: Validations of mRNA expression levels of kdr, nrp-1,
mmp2, egfr, erk2, and survivin in the lung tissues of Tg/Placebo,
Tg/CM/Placebo, and Tg/CM/T1 mice groups by real-time RT-PCR.
A house keeping gene, 𝛽-actin, was used as an internal control. The
quantitative mRNA expression levels based on three independent
repeat experiments of real-time RT-PCR are calculated as mean ±
SEM (𝑛 = 6). ∗𝑃 < 0.05 versus Tg group.
when comparedwith the Tg/CM/Placebo group (Figures 7(a)
and 7(b)). A possible reason for this cell cycle effect is the
reduction of Cyclin A, and Cyclin B that are regulators of
the S and G2/M phases, respectively. T1-induced inhibition
of Cyclins A and B likely decreases the progression of cells
through S and G2/M phases. These results indicate that
the proteins involved in the S to M phase transition in
Tg/CM/Placebo group were suppressed by T1 treatment.
Moreover, we have found that treatment with T1 dramatically
decreases tumor formation in 10-month-old hVEGF-A
165
overexpressing transgenic mice compared with CM treat-
ment alone (Table 1). These results suggest that T1 treatment
significantly reduced the tumor formation due to down-
regulation of cancer cell cycle.
4. Discussion
Earlier studies have shown that Danshen possesses potent
anti-inflammatory, antitumorigenic, and antimetastatic
effects [17]. T1, one of the major diterpenes isolated from
Danshen, shows cytotoxic effects on colon, ovary, lung, and
oral cancer cell lines [33]. Furthermore, T1 has been shown
to significantly inhibit pulmonary cancer cell migration,
invasion, and gelatinase activity in vitro and to reduce
metastasis, angiogenesis, and tumorigenesis in vivo [17]. In
this study, we demonstrated that T1 slowed the inhibition
of CL1-0 lung cancer cell proliferation by decreasing the
expressions of VEGF, Cyclin A, and Cyclin B protein in a
dose-dependent manner (Figure 2); thus T1 warrants further
development as an antiangiogenic agent in the treatment
of lung cancer. Furthermore, Nizamutdinova et al. [34]
demonstrated 10mg/kg T1 did not have any toxic and could
markedly inhibited breast tumor growth. Lee et al. [17]
revealed 0.3mg/kg/day T1 significantly inhibited tumor
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Figure 7: Protein expression levels of VEGF-A, ERK2, Cyclin A,
and Cyclin B in the lung tissues of Tg/CM/Placebo and Tg/CM/T1
groups analyzed by western blots (a) and quantitative assay (b).
GAPDH was used as an internal control. Protein expression was
quantified as mean ± SEM (𝑛 = 6) from three independent repeat
experiments. ∗𝑃 < 0.05 or ∗∗𝑃 < 0.01 versus Tg/CM/Placebo group.
vascularity and fewer tumor metastases in the lung. In
addition, we used 10-month-old transgenic mice carrying
the mccsp-hVEGF-A
165
-sv40 poly(A) transgene, which
overexpresses lung-specific hVEGF-A
165
, to serve as an
animal model treatment with 1mg/kg b.w. T1 to research the
regulatory mechanism of T1 in pulmonary cancer. We found
that CM treatment alone promoted tumor growth. However,
10-month-old hVEGF-A
165
overexpressing transgenic mice
showed a dramatic decrease in solid tumor formation
following a 4-month treatment with T1 three times a
week at 1mg/kg b.w. compared with CM treatment alone.
Histological examination also showed that treatment with
T1 reduced pulmonary tumor formation and inflammation
in hVEGF-A
165
-overexpressing transgenic mice compared
with the Tg/CM/Placebo group (Figure 4). Eberly et al. [35]
demonstrated that pulmonary function is a predictor of
lung cancer mortality. Thus, our results of AHR parameter
detections further demonstrated that treatment with T1 in
VEGF-A165 overexpressing transgenic mice could effectively
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Figure 8: Proposed mechanism of the T1 regulatory pathways in lung tumorigenesis of VEGF-A
165
overexpressed transgenic mice. The
effects of T1 on lung tumor formation are hypothesized to occur through the cell cycle signaling.The diagram shows that T1 might inhibit the
expressions of VEGF-A
165
during signal transduction, as well as reductions of Cyclin A and Cyclin B during S and G2/M cell cycle stages.
reduce pulmonary function damage that may decrease the
incidence of lung cancer.
In the initial stages of cancer, cells keep proliferating and
leading to both nutrient and oxygen deficiencies that result
in a large proportion of cell death. When cancer cells secrete
a large amount of VEGF-A
165
, vasculogenesis is induced so
as to avail sufficient nutrients and oxygen to the tumor, thus
increasing the tumor growth rate [7]. The growth of a solid
tumor is dependent on angiogenesis; thus suppression of
tumor blood vessel formation offers a new option for the
prevention and treatment of cancer. Using IHC staining,
we found that T1 reduced VEGF overexpession in Clara
cells when compared to Tg/CM/Placebo group (Figure 5).
This reduction in VEGF overexpression has an impact on
vasculogenesis and angiogenesis and is a vital factor in tumor
formation, growth, invasion, and metastasis. Nizamutdinova
and his colleagues [36] have shown that T1 effectively inhib-
ited TNF-𝛼-induced VEGF production and VEGF-mediated
tumor formation. In this study, we also found that treatment
with T1 effectively decreased the expression of VEGF, thus
demonstrating its utility as an antiangiogenic agent for the
treatment of pulmonary cancer.
Recently, there has been an extensive evaluation of the
use of plants and their phytochemicals in the treatment of
cancers. In particular, active phytochemicals that function
as cell cycle modulators are gaining widespread attention
[37]. In this study, we have confirmed that T1 can eliminate
pulmonary function damage (Figure 3(b)) and the formation
of pulmonary adenocarcinoma (Figure 4 and Table 1). In
addition, western blot showed that the expressions of Cyclin
A, and Cyclin B in Tg mice were downregulated following
CM/T1 treatment as compared with CM/Placebo treatment
alone (Figure 7). T1-induced inhibition of Cyclin A and
Cyclin B is likely to slow cell cycle progression through
the S and G2/M phases. These results indicate that the
proteins involved in the transition from the S to M phase in
transgenic mice are suppressed by T1. The cell cycle blockage
may be the critical mechanism for the observed effects
following treatment with T1 (Figure 8). This result suggests
that one of the mechanisms of T1 inhibition of pulmonary
cancer growth is through inhibition of the tumor-activated
cell cycle pathway. A previous study [8] demonstrated that
T1 treatment significantly reduced the final prostate tumor
weight which was also associated with downregulated cancer
cell apoptosis, proliferation,AuroraAprotein expression, and
angiogenesis.
In summary, T1 significantly reduces lung adenocarci-
noma tumor growth. This result may be due to an effect of
T1 on the cell cycle and its pathways. This is the first study
to demonstrate that T1 inhibits pulmonary tumor formation
in animal model through down-regulation of cell cycle at
S and G2/M phases. Our research demonstrated that T1 is
an efficacious drug candidate for developing a novel class of
antipulmonary cancer drugs.
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